purine synthesis Inhibitors
1 drugsAbout purine synthesis
Purine synthesis is a fundamental metabolic pathway crucial for cell growth and proliferation by creating adenine and guanine nucleotides, essential for DNA and RNA production.
While no genetic evidence currently links purine synthesis genes to specific diseases, its importance in rapidly dividing cells makes it a target in oncology.
Mercaptopurine, a small molecule approved in 2004, is the sole FDA-approved drug targeting purine synthesis, disrupting DNA synthesis to inhibit cancer cell growth.
Top purine synthesis Drugs
Viatris is the only company with an approved drug targeting purine synthesis.
Low competition suggests a high barrier to entry or limited commercial interest in this pathway.
purine synthesis Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets purine synthesis, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for novel approaches like antibodies or biologics.
purine synthesis Clinical Trials 87 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on purine synthesis. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 5 | 2 | 9 | 71% |
| Phase 2 | 44 | 12 | 7 | 25 | 63% |
| Phase 3 | 23 | 10 | 0 | 13 | 100% |
| Phase 4 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
purine synthesis Drug Approval Timeline (2004 - 2004)
The first and only drug, mercaptopurine, was approved in 2004.
The stagnant approval timeline indicates a saturated market or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 39 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on purine synthesis. A trial counts if an approved drug acting on purine synthesis is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.